NCT03680560 - Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

March 12, 2020

Study Completion Date

March 12, 2020

Conditions

Solid TumorHER-2 Protein Overexpression

Interventions

BIOLOGICAL

ACTR T Cell Product

Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)

DRUG

Trastuzumab

monoclonal antibody targeting HER2

Trial Locations (6)

Miami University Cancer Center, Miami

Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville

The Ohio State University, Columbus

Baylor Scott & White Medical Center, Dallas

MD Anderson Cancer Center, Houston

Yale Smilow Cancer Hospital, New Haven